Yvonne Sherrer, MD
Medical Director/Director of Clinical Research
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL
Medical Director/Director of Clinical Research
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL
Related Videos
What do you think are some of the most important unmet needs in RA?
What do you think are some of the most important unmet needs in RA?
What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials?
What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy? On the basis of what criteria is the decision made to switch to an Il-6 inhibitor or an agent ...
And how do you approach the biologically naive patient?
And how do you approach the biologically naïve patient?
Is there a “one-sequence-fits-all” strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate?
When a suboptimal clinical response has been encountered with TNF or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an ...
How good are the disease outcome metrics recommended by ACR and what are their limitations?
How good are the disease outcome metrics recommended by ACR and what are their limitations?
Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab?
Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab?
What side effects are you most concerned about when using TNFIs or IL-6 inhibitors?
What side effects are you most concerned about when using TNFIs or IL-6 inhibitors?